RxSight, Inc. Announces Preliminary Second Quarter Revenue and Revised 2025 Guidance

Published on July 10, 2025
ALISO VIEJO, Calif.—RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company providing customized vision to patients following cataract surgery, has announced select preliminary financial results for the second quarter of 2025, demonstrating expected revenue of approximately $33.6 million, a decrease of 4 percent compared with the prior-year period, and a decrease of 11 percent compared with the first quarter of 2025. The company also issued revised full-year guidance for 2025, according to the announcement.
Continue reading on website
Other news

Essilor announces release of new progressive lens to improve vision comfort for presbyopes

July 9, 2025
Beginning in July 21, the Varilux Physio extensee and Varilux Physio extensee Classic Edition will be available in the US.

An age-old optometry patient dilemma: Vision or medical?

July 10, 2025
Explaining how different examinations are billed by insurance to patients can make a difference in patient care.